Cargando…
Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis
INTRODUCTION: Immune checkpoint inhibitors (ICI) such as anti-PD-L1 and anti-PD-1 agents have been proven to be effective in various cancers. However, the rate of non-responders is still high in all cancer entities. Therefore, the identification of biomarkers that could help to optimize therapeutic...
Autores principales: | Széles, Ádám, Fazekas, Tamás, Váncsa, Szilard, Váradi, Melinda, Kovács, Petra Terézia, Krafft, Ulrich, Grünwald, Viktor, Hadaschik, Boris, Csizmarik, Anita, Hegyi, Péter, Váradi, Alex, Nyirády, Péter, Szarvas, Tibor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110702/ https://www.ncbi.nlm.nih.gov/pubmed/36385210 http://dx.doi.org/10.1007/s00262-022-03328-9 |
Ejemplares similares
-
High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma
por: Széles, Ádám, et al.
Publicado: (2022) -
Elevated Pre-Treatment Serum MMP-7 Levels Are Associated with the Presence of Metastasis and Poor Survival in Upper Tract Urothelial Carcinoma
por: Kovács, Petra Terézia, et al.
Publicado: (2022) -
Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients—a systematic review and meta-analysis
por: Fazekas, Tamás, et al.
Publicado: (2022) -
High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy
por: Krafft, Ulrich, et al.
Publicado: (2021) -
Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study
por: Váradi, Melinda, et al.
Publicado: (2023)